Pharmacological inhibition of TPL2/MAP3K8 blocks human cytotoxic T lymphocyte effector functions

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Chowdhury, Fatema Z ^a   Estrada, Leonardo D ^a   Murray, Sean ^a   Forman, James ^a   Farrar, J David ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; PROTEIN SERINE THREONINE KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROGRESSION LOCUS 2; UNCLASSIFIED DRUG; MAP3K8 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; SPECIES DIFFERENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL LINEAGE; DENDRITIC CELL; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KNOCKOUT MOUSE; LISTERIA MONOCYTOGENES; LISTERIOSIS; MACROPHAGE; MICROBIOLOGY; PATHOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; CELL LINEAGE; CELLS, CULTURED; DENDRITIC CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-12; LISTERIA MONOCYTOGENES; LISTERIOSIS; MACROPHAGES; MAP KINASE KINASE KINASES; MICE; MICE, KNOCKOUT; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84898662279     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092187     Document Type: Article

References (36)

1. Kaech SM, Wherry EJ (2007) Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during vir (Pubitemid 47418674)
2. Valenzuela J, Schmidt C, Mescher M (2002) The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J Immunol 169: 6842-6849. (Pubitemid 36899269)
3. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174: 4465-4469.
4. Agarwal P, Raghavan A, Nandiwada SL, Curtsinger JM, Bohjanen PR, et al. (2009) Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol 183: 1695-1704.
5. Chang J, Cho JH, Lee SW, Choi SY, Ha SJ, et al. (2004) IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells. J Immunol 172: 2818-2826. (Pubitemid 38263666)
6. Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22: 745-763. (Pubitemid 38680440)
7. Ramos HJ, Davis AM, Cole AG, Schatzle JD, Forman J, et al. (2009) Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates. Blood 113: 5516-5525.
8. Chowdhury FZ, Ramos HJ, Davis LS, Forman J, Farrar JD (2011) IL-12 selectively programs effector pathways that are stably expressed in human CD8+ effector memory T cells in vivo. Blood 118: 3890-3900.
9. Gantke T, Sriskantharajah S, Sadowski M, Ley SC (2012) IkappaB kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev 246: 168-182.
10. Miyoshi J, Higashi T, Mukai H, Ohuchi T, Kakunaga T (1991) Structure and transforming potential of the human cot oncogene encoding a putative protein kinase. Mol Cell Biol 11: 4088-4096. (Pubitemid 21895798)
11. Patriotis C, Makris A, Bear SE, Tsichlis PN (1993) Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci U S A 90: 2251-2255. (Pubitemid 23078604)
12. Gantke T, Sriskantharajah S, Ley SC (2011) Regulation and function of TPL-2, an IkappaB kinase-regulated MAP kinase kinase kinase. Cell Res 21: 131-145.
13. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, et al. (2000) TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103: 1071-1083. (Pubitemid 32040907)
14. Eliopoulos AG, Wang CC, Dumitru CD, Tsichlis PN (2003) Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J 22: 3855-3864. (Pubitemid 36975712)
15. Watford WT, Hissong BD, Durant LR, Yamane H, Muul LM, et al. (2008) Tpl2 kinase regulates T cell interferon-gamma production and host resistance to Toxoplasma gondii. J Exp Med 205: 2803-2812.
16. Fischer AM, Katayama CD, Pages G, Pouyssegur J, Hedrick SM (2005) The role of erk1 and erk2 in multiple stages of T cell development. Immunity 23: 431-443. (Pubitemid 41443444)
17. Graham DB, Bell MP, Huntoon CJ, Griffin MD, Tai X, et al. (2006) CD28 ligation costimulates cell death but not maturation of double-positive thymocytes due to defective ERK MAPK signaling. J Immunol 177: 6098-6107. (Pubitemid 44628825)
18. D'Souza WN, Chang CF, Fischer AM, Li M, Hedrick SM (2008) The Erk2 MAPK regulates CD8 T cell proliferation and survival. J Immunol 181: 7617-7629.
19. Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, et al. (2010) Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol 185: 1037-1044.
20. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
21. Gugasyan R, Horat E, Kinkel SA, Ross F, Grigoriadis G, et al. (2012) The NF-kappaB1 transcription factor prevents the intrathymic development of CD8 T cells with memory properties. EMBO J 31: 692-706.
22. Luciano BS, Hsu S, Channavajhala PL, Lin LL, Cuozzo JW (2004) Phosphorylation of threonine 290 in the activation loop of Tpl2/Cot is necessary but not sufficient for kinase activity. J Biol Chem 279: 52117-52123. (Pubitemid 39656584)
23. Wu J, Green N, Hotchandani R, Hu Y, Condon J, et al. (2009) Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett 19: 3485-3488.
24. Hirata K, Miyashiro M, Ogawa H, Taki H, Tobe K, et al. (2010) Inhibition of tumor progression locus 2 protein kinase decreases lipopolysaccharide-induced tumor necrosis factor alpha production due to the inhibition of the tip-associated protein induction in RAW264.7 cells. Biol Pharm Bull 33: 1233-1237.
25. Hirata K, Taki H, Shinoda K, Hounoki H, Miyahara T, et al. (2010) Inhibition of tumor progression locus 2 protein kinase suppresses receptor activator of nuclear factor-kappaB ligand-induced osteoclastogenesis through down-regulation of the c-Fos and nuclear factor of activated T cells c1 genes. Biol Pharm Bull 33: 133-137.
26. Lawrenz M, Visekruna A, Kuhl A, Schmidt N, Kaufmann SH, et al. (2012) Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease? Mucosal Immunol 5: 129-139.
27. Yang J, Zhu H, Murphy TL, Ouyang W, Murphy KM (2001) IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production. Nat Immunol 2: 157-164. (Pubitemid 33707936)
28. Symons A, Beinke S, Ley SC (2006) MAP kinase kinase kinases and innate immunity. Trends Immunol 27: 40-48. (Pubitemid 43083563)
29. Tsatsanis C, Vaporidi K, Zacharioudaki V, Androulidaki A, Sykulev Y, et al. (2008) Tpl2 and ERK transduce antiproliferative T cell receptor signals and inhibit transformation of chronically stimulated T cells. Proc Natl Acad Sci U S A 105: 2987-2992. (Pubitemid 351723655)
30. Raman M, Cobb MH (2003) MAP kinase modules: many roads home. Curr Biol 13: R886-888. (Pubitemid 37425200)
31. Taylor PC, Feldmann M (2009) Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5: 578-582.
32. Lindstrom TM, Robinson WH (2010) A multitude of kinases-which are the best targets in treating rheumatoid arthritis? Rheum Dis Clin North Am 36: 367-383.
33. Hall JP, Kurdi Y, Hsu S, Cuozzo J, Liu J, et al. (2007) Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem 282: 33295-33304. (Pubitemid 350159547)
34. Hu Y, Green N, Gavrin LK, Janz K, Kaila N, et al. (2006) Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis. Bioorg Med Chem Lett 16: 6067-6072. (Pubitemid 44667801)
35. Cohen P (2009) Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 21: 317-324.
36. Gaestel M, Kotlyarov A, Kracht M (2009) Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov 8: 480-499.